Delirium – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Delirium Market Outlook

Thelansis’s “Delirium Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Delirium treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Delirium Overview

Delirium is a severe neuropsychiatric condition characterized by a sudden onset of attention deficits and cognitive impairments. Patients often exhibit varying levels of consciousness, ranging from reduced responsiveness akin to a near-coma state to heightened vigilance and extreme restlessness. Additionally, they may undergo distressing psychotic symptoms, including hallucinations, delusions, and mood alterations. The intensity and presence of delirium symptoms tend to fluctuate. This condition brings considerable distress to both patients and their caregivers. It arises from multiple potential triggers, such as acute medical illnesses, drug-related issues, withdrawal, trauma, or surgical procedures. While most causes originate outside the brain, instances of delirium stemming from primary neurological causes like strokes are acknowledged. The duration of delirium varies widely, with most episodes spanning a few days, although some cases persist for weeks or even months in about 20% of individuals. The term "subsyndromal delirium" describes patients who exhibit some features of delirium but do not meet all the diagnostic criteria. Several predisposing risk factors contribute to delirium, including advanced age, cognitive impairments like dementia, frailty, underlying health conditions such as cardiovascular and renal diseases, psychiatric disorders including depression, alcohol use, poor nutritional status, and sensory impairments like vision and hearing problems. Delirium manifests in three subtypes: hyperactive, hypoactive, and mixed. The hyperactive subtype presents with agitation, disorientation, delusions, and possible hallucinations. This appearance can be mistaken for schizophrenia, agitated dementia, or a psychotic disorder. The hypoactive subtype involves subdued confusion, disorientation, apathy, and quietness. In these cases, delirium might be overlooked or confused with depression or dementia. The mixed subtype showcases fluctuation between hyperactive and hypoactive features. Managing delirium symptoms may involve employing antipsychotic medications to control agitation and hallucinations and improve attention and orientation abilities (sensorium clearing).

• Delirium affects almost 20% of patients over 75 in medical inpatient settings. In intensive care units (ICUs), the prevalence is significantly higher, with rates exceeding 80% among mechanically ventilated patients. Additionally, postoperative delirium occurs in 13% to over 50% of surgical patients.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: